Genomma Lab Internacional, SAB de CV (BMV: LABB), a Mexico-based over-the-counter pharmaceutical, generic drugs and personal care products company, announced on Thursday a cash dividend of MXN0.200000 per share on its common stock.
This represents a total amount of MXN200m.
The dividend is payable to shareholders of record of the applicable circulating shares at the close of business on 14 March 2025.
Genomma Lab intends to make dividend payments on a quarterly basis.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government